​
​

Bristol-Myers Squibb Company (BMY) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Bristol-Myers Squibb Company Revenue Highlights

Latest Revenue (Y)

$45.01B

Latest Revenue (Q)

$11.89B

Main Segment (Y)

Eliquis

Main Geography (Y)

UNITED STATES

Bristol-Myers Squibb Company Revenue by Period

Bristol-Myers Squibb Company Revenue by Year

DateRevenueChange
2023-12-31$45.01B-2.50%
2022-12-31$46.16B-0.49%
2021-12-31$46.38B9.09%
2020-12-31$42.52B62.62%
2019-12-31$26.14B15.89%
2018-12-31$22.56B8.59%
2017-12-31$20.78B6.94%
2016-12-31$19.43B17.31%
2015-12-31$16.56B4.29%
2014-12-31$15.88B-3.09%
2013-12-31$16.39B-7.01%
2012-12-31$17.62B-17.05%
2011-12-31$21.24B9.03%
2010-12-31$19.48B3.59%
2009-12-31$18.81B-8.69%
2008-12-31$20.60B6.46%
2007-12-31$19.35B8.00%
2006-12-31$17.91B-6.73%
2005-12-31$19.21B-0.89%
2004-12-31$19.38B-7.25%
2003-12-31$20.89B15.32%
2002-12-31$18.12B-6.71%
2001-12-31$19.42B6.63%
2000-12-31$18.22B-9.92%
1999-12-31$20.22B10.60%
1998-12-31$18.28B9.48%
1997-12-31$16.70B10.86%
1996-12-31$15.06B9.43%
1995-12-31$13.77B14.88%
1994-12-31$11.98B5.00%
1993-12-31$11.41B-

Bristol-Myers Squibb Company generated $45.01B in revenue during NA 2023, up -2.50% compared to the previous quarter, and up 199.49% compared to the same period a year ago.

Bristol-Myers Squibb Company Revenue by Quarter

DateRevenueChange
2024-09-30$11.89B-2.53%
2024-06-30$12.20B2.83%
2024-03-31$11.87B3.38%
2023-12-31$11.48B4.66%
2023-09-30$10.97B-2.32%
2023-06-30$11.23B-0.98%
2023-03-31$11.34B-0.60%
2022-12-31$11.41B1.68%
2022-09-30$11.22B-5.63%
2022-06-30$11.89B2.05%
2022-03-31$11.65B-2.81%
2021-12-31$11.98B3.11%
2021-09-30$11.62B-0.68%
2021-06-30$11.70B5.69%
2021-03-31$11.07B0.05%
2020-12-31$11.07B5.01%
2020-09-30$10.54B4.06%
2020-06-30$10.13B-6.05%
2020-03-31$10.78B35.70%
2019-12-31$7.95B32.26%
2019-09-30$6.01B-4.24%
2019-06-30$6.27B5.96%
2019-03-31$5.92B-0.89%
2018-12-31$5.97B4.96%
2018-09-30$5.69B-0.23%
2018-06-30$5.70B9.84%
2018-03-31$5.19B-4.70%
2017-12-31$5.45B3.71%
2017-09-30$5.25B2.14%
2017-06-30$5.14B4.36%
2017-03-31$4.93B-5.99%
2016-12-31$5.24B6.52%
2016-09-30$4.92B1.05%
2016-06-30$4.87B10.93%
2016-03-31$4.39B2.43%
2015-12-31$4.29B5.36%
2015-09-30$4.07B-2.26%
2015-06-30$4.16B3.02%
2015-03-31$4.04B-5.10%
2014-12-31$4.26B8.59%
2014-09-30$3.92B0.82%
2014-06-30$3.89B2.05%
2014-03-31$3.81B-14.19%
2013-12-31$4.44B9.25%
2013-09-30$4.07B0.42%
2013-06-30$4.05B5.66%
2013-03-31$3.83B-8.59%
2012-12-31$4.19B12.18%
2012-09-30$3.74B-15.91%
2012-06-30$4.44B-15.39%
2012-03-31$5.25B-3.72%
2011-12-31$5.45B2.04%
2011-09-30$5.34B-1.64%
2011-06-30$5.43B8.44%
2011-03-31$5.01B-1.96%
2010-12-31$5.11B6.52%
2010-09-30$4.80B0.63%
2010-06-30$4.77B-0.81%
2010-03-31$4.81B64.51%
2009-12-31$2.92B-46.75%
2009-09-30$5.49B1.91%
2009-06-30$5.38B7.36%
2009-03-31$5.01B-4.46%
2008-12-31$5.25B-0.10%
2008-09-30$5.25B0.98%
2008-06-30$5.20B0.42%
2008-03-31$5.18B5.86%
2007-12-31$4.89B-

Bristol-Myers Squibb Company generated $11.89B in revenue during Q3 2024, up -2.53% compared to the previous quarter, and up 105.93% compared to the same period a year ago.

Bristol-Myers Squibb Company Revenue Breakdown

Bristol-Myers Squibb Company Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 22Dec 21Dec 20Dec 19Dec 18
Yervoy$2.13B$2.03B$1.68B$1.49B$1.33B
Abecma$388.00M$164.00M---
Abraxane$811.00M$1.18B$1.25B$166.00M-
Breyanzi$182.00M$87.00M---
Eliquis$11.79B$10.76B$9.17B$7.93B$6.44B
Empliciti$296.00M$334.00M$381.00M$357.00M$247.00M
Inrebic$85.00M$74.00M$55.00M$5.00M-
Mature Products And All Other$1.75B$1.90B$1.31B$1.67B$1.63B
Onureg$124.00M$73.00M$17.00M--
Opdivo$8.25B$7.52B$6.99B$7.20B$6.74B
Opdualag$252.00M----
Orencia$3.46B$3.31B$3.16B$2.98B$2.71B
Pomalyst/Imnovid$3.50B$3.33B$3.07B$322.00M-
Reblozyl$717.00M$551.00M$274.00M--
Sotyktu$8.00M----
Camzyos$24.00M----
Sprycel$2.17B$2.12B$2.14B$2.11B$2.00B
Revlimid$9.98B$12.82B$12.11B$1.30B-
Zeposia$250.00M$134.00M$12.00M--
Baraclude--$447.00M$555.00M$744.00M
Vidaza--$455.00M$58.00M-
Hepatitis C Portfolio----$17.00M
Sustiva Franchise----$283.00M
Reyataz----$427.00M

Bristol-Myers Squibb Company's latest annual revenue breakdown by segment (product or service), as of Dec 22: Eliquis (25.54%), Revlimid (21.62%), Opdivo (17.87%), Pomalyst/Imnovid (7.58%), Orencia (7.50%), Sprycel (4.69%), Yervoy (4.62%), Mature Products And All Other (3.79%), Abraxane (1.76%), Reblozyl (1.55%), Abecma (0.84%), Empliciti (0.64%), Opdualag (0.55%), Zeposia (0.54%), Breyanzi (0.39%), Onureg (0.27%), Inrebic (0.18%), Camzyos (0.05%), and Sotyktu (0.02%).

Quarterly Revenue by Product

Product/ServiceJun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Sep 18Jun 18
Camzyos$46.00M-------------------
Sotyktu$25.00M-------------------
Sprycel$458.00M$429.00M$578.00M$560.00M$544.00M$483.00M$555.00M$551.00M$541.00M$470.00M$564.00M$544.00M$511.00M$521.00M$549.00M$558.00M$544.00M$459.00M$491.00M$535.00M
Yervoy$585.00M$508.00M$568.00M$523.00M$525.00M$515.00M$545.00M$515.00M$510.00M$456.00M$471.00M$446.00M$369.00M$396.00M$385.00M$353.00M$367.00M$384.00M$382.00M$315.00M
Zeposia$100.00M$78.00M$79.00M$69.00M$66.00M$36.00M$48.00M$40.00M$28.00M$18.00M$9.00M$2.00M$1.00M-------
Abecma$132.00M$147.00M$125.00M$107.00M$89.00M$67.00M$69.00M$71.00M$24.00M-----------
Breyanzi$100.00M$71.00M$55.00M$44.00M$39.00M$44.00M$40.00M$30.00M$17.00M-----------
Eliquis$3.20B$3.42B$2.69B$2.65B$3.23B$3.21B$2.67B$2.41B$2.79B$2.89B$2.27B$2.10B$2.16B$2.64B$2.03B$1.93B$2.04B$1.93B$1.58B$1.65B
Inrebic$27.00M$25.00M$23.00M$21.00M$23.00M$18.00M$20.00M$22.00M$16.00M$16.00M$15.00M$13.00M$15.00M$12.00M------
Mature and Other Brands$472.00M$467.00M$441.00M$435.00M$462.00M---------------
Onureg$44.00M$34.00M$37.00M$32.00M$32.00M$23.00M$25.00M$21.00M$12.00M$15.00M$14.00M$3.00M--------
Opdivo$2.15B$2.20B$2.22B$2.05B$2.06B$1.92B$1.99B$1.91B$1.91B$1.72B$1.79B$1.78B$1.65B$1.77B$1.76B$1.82B$1.82B$1.80B$1.79B$1.63B
Abraxane$258.00M$239.00M$179.00M$177.00M$241.00M$214.00M$305.00M$266.00M$296.00M$314.00M$297.00M$342.00M$308.00M$300.00M------
Opdualag$154.00M$117.00M$104.00M$84.00M$58.00M$6.00M--------------
Orencia$927.00M$764.00M$913.00M$883.00M$876.00M$792.00M$864.00M$870.00M$814.00M$758.00M$867.00M$826.00M$750.00M$714.00M$792.00M$767.00M$778.00M$640.00M$675.00M$711.00M
Pomalyst/Imnovid$847.00M$832.00M$877.00M$886.00M$908.00M$826.00M$854.00M$851.00M$854.00M$773.00M$835.00M$777.00M$745.00M$713.00M------
Reblozyl$234.00M$206.00M$199.00M$190.00M$172.00M$156.00M$151.00M$160.00M$128.00M$112.00M$115.00M$96.00M$55.00M$8.00M------
Revlimid$1.47B$1.75B$2.26B$2.42B$2.50B$2.80B$3.33B$3.35B$3.20B$2.94B$3.28B$3.03B$2.88B$2.92B------
Empliciti--$71.00M$73.00M$77.00M$75.00M$81.00M$82.00M$86.00M$85.00M$91.00M$96.00M$97.00M$97.00M$94.00M$89.00M$91.00M$83.00M$59.00M$64.00M
Mature Products And All Other------$903.00M$339.00M$319.00M$339.00M$279.00M$287.00M$331.00M$418.00M$356.00M$350.00M$481.00M$487.00M--
Vidaza-------$36.00M$45.00M$54.00M$65.00M$106.00M$126.00M$158.00M------
Baraclude-------$105.00M$109.00M$113.00M$104.00M$100.00M$121.00M$122.00M$122.00M$145.00M$147.00M$141.00M$175.00M$179.00M
Sustiva Franchise------------------$72.00M$73.00M
Reyataz------------------$87.00M$117.00M
Other------------------$382.00M$421.00M
Hepatitis C Portfolio------------------$-2.00M$12.00M

Bristol-Myers Squibb Company's latest quarterly revenue breakdown by segment (product or service), as of Jun 23: Eliquis (28.54%), Opdivo (19.11%), Revlimid (13.08%), Orencia (8.26%), Pomalyst/Imnovid (7.54%), Yervoy (5.21%), Mature and Other Brands (4.20%), Sprycel (4.08%), Abraxane (2.30%), Reblozyl (2.08%), Opdualag (1.37%), Abecma (1.18%), Zeposia (0.89%), Breyanzi (0.89%), Camzyos (0.41%), Onureg (0.39%), Inrebic (0.24%), and Sotyktu (0.22%).

Bristol-Myers Squibb Company Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 22Dec 21Dec 20Dec 19Dec 18
European Union$13.50B$10.69B$9.85B$6.27B$5.66B
Other Region$834.00M$852.00M$631.00M$524.00M$584.00M
UNITED STATES$31.83B$29.21B$26.58B$15.34B$12.59B
Europe$13.50B----
Rest Of World-$5.63B$5.46B$4.01B$3.73B

Bristol-Myers Squibb Company's latest annual revenue breakdown by geography, as of Dec 22: UNITED STATES (53.35%), European Union (22.62%), Europe (22.62%), and Other Region (1.40%).

Quarterly Revenue by Country

CountryJun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Sep 18Jun 18
UNITED STATES$7.89B$8.03B$7.92B$7.94B$8.27B$7.69B$7.52B$7.30B$7.39B$7.01B$6.78B$6.54B$6.49B$6.77B$4.75B$3.47B$3.67B$3.45B$3.23B$3.23B
Rest Of World$3.16B$1.31B$1.46B$1.39B$1.44B$1.35B$1.43B$1.36B$1.33B$1.33B$1.18B$976.00M$988.00M$874.00M$932.00M$923.00M----
Other Region$175.00M$155.00M$200.00M$215.00M$192.00M$227.00M$221.00M$276.00M$191.00M$164.00M$162.00M$184.00M$172.00M$113.00M$166.00M$114.00M$127.00M$117.00M--
Europe-----$2.41B$2.66B$2.69B$1.36B$1.41B----------
European Union---------$2.55B$2.70B$2.45B$2.14B$2.57B$1.85B$1.45B$1.49B$1.48B--
Other------------------$159.00M$143.00M

Bristol-Myers Squibb Company's latest quarterly revenue breakdown by geography, as of Jun 23: UNITED STATES (70.29%), Rest Of World (28.15%), and Other Region (1.56%).

Bristol-Myers Squibb Company Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
JNJJohnson & Johnson$85.15B$22.47B
MRKMerck$60.12B$16.66B
PFEPfizer$58.50B$17.70B
ABBVAbbVie$54.32B$14.46B
BMYBristol-Myers Squibb Company$45.01B$11.89B
LLYEli Lilly and Company$34.12B$11.44B
AMGNAmgen$28.19B$8.50B
GILDGilead Sciences$27.12B$7.55B
BIIBBiogen$9.84B$2.47B

BMY Revenue FAQ

What is Bristol-Myers Squibb Company’s yearly revenue?

Bristol-Myers Squibb Company's yearly revenue for 2023 was $45.01B, representing a decrease of -2.50% compared to 2022. The company's yearly revenue for 2022 was $46.16B, representing a decrease of -0.49% compared to 2021. BMY's yearly revenue for 2021 was $46.38B, representing an increase of 9.09% compared to 2020.

What is Bristol-Myers Squibb Company’s quarterly revenue?

Bristol-Myers Squibb Company's quarterly revenue for Q3 2024 was $11.89B, a -2.53% decrease from the previous quarter (Q2 2024), and a 8.44% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $12.2B, a 2.83% increase from the previous quarter (Q1 2024), and a 8.69% increase year-over-year (Q2 2023). BMY's quarterly revenue for Q1 2024 was $11.86B, a 3.38% increase from the previous quarter (Q4 2023), and a 4.66% increase year-over-year (Q1 2023).

What is Bristol-Myers Squibb Company’s revenue growth rate?

Bristol-Myers Squibb Company's revenue growth rate for the last 3 years (2021-2023) was -2.97%, and for the last 5 years (2019-2023) was 72.14%.

What are Bristol-Myers Squibb Company’s revenue streams?

Bristol-Myers Squibb Company's revenue streams in c 22 are Yervoy, Abecma, Abraxane, Breyanzi, Eliquis, Empliciti, Inrebic, Mature Products And All Other, Onureg, Opdivo, Opdualag, Orencia, Pomalyst/Imnovid, Reblozyl, Sotyktu, Camzyos, Sprycel, Revlimid, and Zeposia. Yervoy generated $2.13B in revenue, accounting 4.62% of the company's total revenue, up 5.18% year-over-year. Abecma generated $388M in revenue, accounting 0.84% of the company's total revenue, up 136.59% year-over-year. Abraxane generated $811M in revenue, accounting 1.76% of the company's total revenue, down -31.33% year-over-year. Breyanzi generated $182M in revenue, accounting 0.39% of the company's total revenue, up 109.20% year-over-year. Eliquis generated $11.79B in revenue, accounting 25.54% of the company's total revenue, up 9.54% year-over-year. Empliciti generated $296M in revenue, accounting 0.64% of the company's total revenue, down -11.38% year-over-year. Inrebic generated $85M in revenue, accounting 0.18% of the company's total revenue, up 14.86% year-over-year. Mature Products And All Other generated $1.75B in revenue, accounting 3.79% of the company's total revenue, down -7.95% year-over-year. Onureg generated $124M in revenue, accounting 0.27% of the company's total revenue, up 69.86% year-over-year. Opdivo generated $8.25B in revenue, accounting 17.87% of the company's total revenue, up 9.65% year-over-year. Opdualag generated $252M in revenue, accounting 0.55% of the company's total revenue Orencia generated $3.46B in revenue, accounting 7.50% of the company's total revenue, up 4.78% year-over-year. Pomalyst/Imnovid generated $3.5B in revenue, accounting 7.58% of the company's total revenue, up 4.95% year-over-year. Reblozyl generated $717M in revenue, accounting 1.55% of the company's total revenue, up 30.13% year-over-year. Sotyktu generated $8M in revenue, accounting 0.02% of the company's total revenue Camzyos generated $24M in revenue, accounting 0.05% of the company's total revenue Sprycel generated $2.16B in revenue, accounting 4.69% of the company's total revenue, up 2.27% year-over-year. Revlimid generated $9.98B in revenue, accounting 21.62% of the company's total revenue, down -22.17% year-over-year. Zeposia generated $250M in revenue, accounting 0.54% of the company's total revenue, up 86.57% year-over-year.

What is Bristol-Myers Squibb Company’s main source of revenue?

For the fiscal year ending Dec 22, the largest source of revenue of Bristol-Myers Squibb Company was Eliquis. This segment made a revenue of $11.79B, representing 25.54% of the company's total revenue.